Headache, Migraine Clinical Trial
Official title:
Efficacy of Nasal Migraine Cocktail Used In Pediatric Emergency Department: A Clinical Trial
The purpose of this study is to determine if intranasal (IN) Ketorolac in combination with oral Prochlorperazine and Diphenhydramine is non-inferior to current migraine management which involves use of intravenous (IV) Ketorolac and oral adjuncts Prochlorperazine and diphenhydramine for reducing pain intensity in children with migraine headaches. The investigators hypothesize that IN ketorolac combined with these oral adjuncts is non-inferior to IV ketorolac and oral adjuncts in reducing acute migraine headache pain by a minimum clinically significant difference within 60 minutes of administration.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | January 1, 2026 |
Est. primary completion date | July 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility | Inclusion Criteria: - A headache that fulfills at least three of the six following criteria: i) moderate to severe episode of impaired daily activities; ii) focal localization of headache (focal meaning unilateral, bifrontal, bitemporal, or biparietal); iii) pulsatile description; iv) nausea or vomiting or abdominal pain; v) photophobia or phonophobia or avoidance of light and noise; and vi) symptoms increasing with activity or resolving by rest - Pain 4/10 on the validated Faces Pain Scale - Headache duration between 1 and 72 hours Exclusion Criteria: - Any contraindication to receiving ketorolac (e.g. known allergy, known peptic ulcer disease, gastrointestinal bleeding, hepatic impairment (patients with known aspartate aminotransferase (AST) > 60 units/L "OR" alanine aminotransferase (ALT) > 40 units/L "OR" total bilirubin > 1.2 mg/dl) - Renal impairment (patients with known estimated glomerular filtration rate of < 90 mL/min/1.73m2) - Known bleeding disorders - Receipt of an NSAID (e.g. ibuprofen, naproxen, naproxen/sumatriptan) within previous six hours - Receipt of oral prochlorperazine or metoclopramide or diphenhydramine within 12 hours prior to presentation - Presence of intranasal obstruction (e.g. mucous or blood) that cannot be readily cleared using suction or nose blowing - Inability to speak English - Patients with a concurrent diagnosis of traumatic brain injury - Unable to complete self-report measures of pain or questionnaires (e.g. developmental delay, neurologic impairment) - Critical illness - Frequent use of drugs for headache (defined as regular intake of analgesics for acute headaches on more than 10 days per month) - Patients refusing to take oral adjuncts or unable to tolerate oral medications will be excluded from the trial. - Patients currently on the following medications will also be excluded from the study as there are contraindications for use of Ketorolac with use of these medications: antiplatelets (i.e. salicylates, aspirin, clopidogrel, ticagrelor), Anticoagulants (i.e. warfarin, rivaroxaban, apixaban, dabigatran, enoxaparin, and heparin), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (losartan, Lisinopril), cyclosporine or tacrolimus, furosemide, bumetanide, spironolactone, hydrochlorothiazide, digoxin, lithium, methotrexate, probenecid, some selective serotonin reuptake inhibitors (including i.e. citalopram, escitalopram, sertraline), antipsychotics (i.e. Quetiapine, risperidone, aripiprazole, haloperidol), tranylcypromine, oxybates, oral potassium citrate, and Anticholinergics (i.e. amantadine). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | Assertio Holdings, Inc |
Kuensting LL, DeBoer S, Holleran R, Shultz BL, Steinmann RA, Venella J. Difficult venous access in children: taking control. J Emerg Nurs. 2009 Sep;35(5):419-24. doi: 10.1016/j.jen.2009.01.014. Epub 2009 Mar 21. No abstract available. — View Citation
Tsze DS, Lubell TR, Carter RC, Chernick LS, DePeter KC, McLaren SH, Kwok MY, Roskind CG, Gonzalez AE, Fan W, Babineau SE, Friedman BW, Dayan PS. Intranasal ketorolac versus intravenous ketorolac for treatment of migraine headaches in children: A randomized clinical trial. Acad Emerg Med. 2022 Apr;29(4):465-475. doi: 10.1111/acem.14422. Epub 2021 Dec 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in pain on the 10 point Faces Pain Scale-Revised in 2 hours | The Faces Pain Scale - Revised. This is a 10-point pain scale (0-10) that has been validated for the use in children greater than 4 years of age in the ED; is one of the self-report measures of pain recommended for research in children; and is commonly used as the primary outcome in Emergency Department research. Lower numbers are better outcomes. | Baseline (within 15 minutes prior to receiving the study drug or as close to this time frame as possible) and then at 10 minutes, 30 minutes, 60 minutes, and 120 minutes (or as close to this time frame as possible) | |
Secondary | Response Rate- 2/10 score difference of pain on the Faces Pain Scale- Revised | Response rate is defined as the number of participants with a pain scale change of at least 2/10 on The Faces Pain Scale - Revised from baseline to 10 minutes after medication given. The Faces Pain Scale - Revised. The Faces Pain Scale - Revised is a 10-point pain scale that has been validated for the use in children greater than 4 years of age in the Emergency Department; is one of the self-report measures of pain recommended for research in children; and is commonly used as the primary outcome in Emergency Department research. The lower numbers on this scale report better outcomes. | 10 minutes after medication given |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05503082 -
Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies
|
Phase 4 | |
Completed |
NCT04905654 -
Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura
|
N/A | |
Completed |
NCT04111484 -
Adrenomedullin Effect on Migraine Without Patients
|
N/A | |
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT03337620 -
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
|
Phase 3 | |
Completed |
NCT02259387 -
Adolescents With Migraine: What's Stress Got To Do With It?
|
||
Completed |
NCT05658185 -
Migraine Difficult to Treat: the Importance of Psychological Care in the Chronic Patient
|
N/A | |
Completed |
NCT05001399 -
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain
|
N/A | |
Completed |
NCT03490500 -
Using the S100B Protein for Emergency Headache Management Care (S100)
|
||
Completed |
NCT03075020 -
Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura.
|
N/A | |
Recruiting |
NCT03472092 -
Mind and Body Approaches to Pain Reduction in Youth With Migraine
|
Phase 2 | |
Enrolling by invitation |
NCT04976985 -
Osteopathic Manipulative Treatment and Migraine Headaches
|
N/A | |
Active, not recruiting |
NCT04372264 -
Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache
|
Phase 4 | |
Recruiting |
NCT04623203 -
The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
|
||
Completed |
NCT04577443 -
The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties.
|
N/A | |
Completed |
NCT03560024 -
The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers
|
N/A | |
Completed |
NCT03228355 -
Headache Inducing Effect of Cromakalim in Migraine Patients
|
N/A | |
Completed |
NCT02438553 -
Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain
|
N/A | |
Recruiting |
NCT03577548 -
Influence of Main Psychological and Social Factors on Primary Headaches
|
||
Recruiting |
NCT04715685 -
Mind Body Balance for Pediatric Migraine
|
N/A |